Divestment of the cancer business may be a deterrent for Takeda

Any deal would likely bid Irish rare disease specialist at close to €57bn

Irish domiciled company to get ‘customised training programmes’ from universities

The pharma company upgrades guidance after strong first half

Firm planning to create 150 new jobs in State reports product sales up 110% to $3.4bn

Dublin-headquartered pharma giant is creating 400 jobs as part of the investment

Irish-domiciled business says cost savings in $32bn Baxalta deal 40% more than expected

Shareholders are rejecting proposals to ramp up CEOs’ rewards

Republic a ‘strategically important location’ for the company

Shire shares slide 8% as analysts concerned about ambitious savings target from merger

Deal will give Dublin-based pharma group access to treatment for inflammatory disease

CEO Flemming Ornskov refused to be drawn on whether drugmaker will pitch new higher offer

Shire CEO confident Baxalta shareholders are open to a deal

Investor says shareholders in Dublin company may back increase from current $45.23 a share offer to $50 but some unease over scale of acquisition